Abrysvo® RSV maternal vaccine advice for health professionals
23 Jan 2025
- From Monday, 3 February 2025 a new RSV maternal vaccine, Abrysvo®, will be available on the National Immunisation Program (NIP) for pregnant women from 28 to 36 weeks gestation.
- Maternal vaccination with Abrysvo® protects newborn babies from severe RSV in the first six months of life through the transfer of maternal antibodies to the foetus during pregnancy.
- Abrysvo® is the only RSV vaccine approved for use in pregnant women. (Note: Arexvy® vaccine should not be given to pregnant women.)
- A single dose of Abrysvo® should be offered to all pregnant women year round at the 28-week antenatal appointment and can be given at the same time as pertussis and influenza vaccines.
- From 17 March 2025, infants not protected from RSV by maternal vaccination or who have certain medical risk factors for severe RSV disease, will be offered nirsevimab, a monoclonal antibody.
As part of the NSW RSV Prevention Program, NSW Health advise health professionals Abrysvo®, a new RSV maternal vaccine, will be available on the National Immunisation Program (NIP) for pregnant women from 28 to 36 weeks gestation from 3 February 2025.
The new NSW RSV Prevention Program aims to protect newborn and at-risk infants against RSV and reduce RSV-associated infections and hospitalisations through the transfer of maternal antibodies to the fetus during pregnancy, or provision of passive immunisation to infants not protected by maternal vaccination and eligible at-risk infants.
NSW Health have issued a fact sheet providing advice for health professionals. Download the fact sheet for recommendations on timing, where to find clinical decision aids, ordering supplies and reporting in the Australian Immunisation Register (AIR) and “yellow” antenatal card.
Read NSW Health Fact Sheet for health professionals
Visit NSW Health for the latest NSW RSV Prevention Program guidance for health professionals.